Parte, Capitolo, Paragrafo
1 I, 1,1(8) | m., Organs from animals for man, Int. Arch. Allergy
2 I, 1,1(9) | m., Organs from animals for man, Int. Arch. Allergy
3 I, 1,1(9) | as Potential Organ Donor for Man. In: cooper dkc, kemp
4 I, 1,1(10) | Life supporting function for over one month of a transgenic
5 I, 1,1(10) | transgenic pig model system for the study of discordant
6 I, 2,2(15) | antibodies: implications for discordant xenografting
7 I, 2,2(18) | Accommodation: a working paradigm for progressing toward clinical
8 I, 2,2(18) | accelerating factor. Potential for prevention of xenograft
9 I, 2,2(19) | transgenic pig model system for the study of discordant
10 I, 2,2(19) | as potential organ donors for humans, Nature Medicine
11 I, 2,2(19) | transgenic pig as a model for the prevention of xenogeneic
12 I, 2,2(19) | production of pigs transgenic for a human regulator of complement
13 I, 2,2(21) | and potential therapies for delayed xenograft rejection,
14 I, 2,2(23) | Life supporting function for over one month of a transgenic
15 I, 2,3(28) | and potential therapies for delayed xenograft rejection,
16 I, 2,3(33) | Life supporting function for over one month of a transgenic
17 I, 2,3(37) | Life supporting function for over one month of a transgenic
18 I, 2,4(40) | production Specification for xenotransplantation, Ann
19 I, 2,4(43) | group, et al, 1999, Search for cross-species transmission
20 I, 2,5(45) | gene expression: prospects for gene therapy, Curr Opin
21 I, 3,6(47) | H., Xenotransplantation for CNS repair: immunological
22 I, 3,6(48) | multicenter clinical trial for acute liver failure, Transpl.
23 I, 3,6(49) | the international society for heart and lung transplantation.
24 I, 3,6(50) | Life supporting function for over one month of a transgenic
25 II, 1,8(57) | London; Regan T., The case for Animal Rights, 1983, London,
26 II, 2,12(65)| Drug Administration, Center for Biologics Evaluation and
27 II, 2,12(65)| products in humans: guidance for industry (Draft, February
28 II, 2,16(71)| H., Polcrack L., Respect for persons, informed consent
29 II, 3,21(75)| Committee and applications for clinical trials will need
30 II, 3,21(75)| the newly formed Agency for the Security of Health Products
|